Androgen receptor (AR) is a master regulator of prostate cancer (PCa), and therefore is a pivotal drug target for the treatment of PCa including its castration-resistance form (CRPC). The development of acquired resistance is a major challenge in the use of the current antiandrogens. The recent advancements in inhibiting AR activity with small molecules specifically designed to target areas distinct from the receptor's androgen binding site are carefully discussed. Our new classes of AR inhibitors of AF2 and BF3 functional sites and DBD domains designed using cheminformatics techniques are promising to circumvent various AR-dependent resistance mechanisms.
Molecular informatics. 2018 May 07 [Epub ahead of print]
Fuqiang Ban, Kush Dalal, Eric LeBlanc, Hélène Morin, Paul S Rennie, Artem Cherkasov
Vancouver Prostate Centre (VPC), 2660 Oak Street, Vancouver, British Columbia, V6H3Z6, Canada.